Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients

Dr Chi-Joan How speaks to ecancer about the antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients.


She mentions that the efficacy of COVID-19 vaccines in cancer populations remain unknown.


Myeloproliferative neoplasms remain a vulnerable patient population and are immunocompromised due to impaired innate and adaptive immunity, heightened inflammation, and effects of ongoing treatment.


Dr How says that the evaluated antibody and T-cell responses in MPN patients following completion of the BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine series.


She then talks about the methodology and results of the study.


Dr How concludes by discussing what is next for the study and how these results can impact patient care.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php